Waters

¹Manchester Metropolitan University, Manchester, UNITED KINGDOM, ²The Royal Free Hospital, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, UNITED KINGDOM, ⁴Waters Corporation, Manchester, UNITED KINGDOM, ⁵Health Protection Agency, London, ⁵Health Protection Agency, London, ⁵Health Protection Agency, London, ⁵Health Protection Agency, ⁵Health P

Abstract

Background: The incidence of superficial and deep fungal infections have been on the increase over the last decade, so much so that *Candida* species are now the fourth most common cause of bloodstream infections in the United States, it is paramount in these cases that a rapid identification is possible to ensure an appropriate effective course of treatment is made available to the patient. Traditional fungal and yeast identification methods usually involve biochemical, morphological and physiological tests, that can be time consuming and labour intensive. These techniques also require a high level of skill, training and often the personal judgement/experience of a clinical mycologist. Commercial kits are available for the more clinically relevant yeasts and fungi including Candida species, these however are mainly based on biochemical tests and/or colour interpretation, often only covering a narrow range of species and/or require a 24-72h following culture to obtain an identification.

MALDI-TOF MS has recently shown great success in bacterial identification and this paper aims to explore the possibility of developing the technique to include yeasts, in particular *Candida species*. The use of MALDI-TOF MS has the advantage of reducing culture time to 24 hours, and identification to within minutes.

Method: Different species of *Candida* were cultured on a variety of culture medium; intact *Candida* cells were transferred directly from the medium plate to a MALDI target plate and overlaid with MALDI matrix. The co-crystallised sample was then irradiated with a N_2 laser and the resulting plume of positive ions separated using time-of-flight mass spectrometry, which produces a mass spectral fingerprint.

Results: The mass spectral fingerprint patterns produced were interrogated for characteristic properties, to assess the most appropriate culture medium and culture conditions suitable for identification purposes. **Conclusions**: Using MALDI-TOF MS it is possible to obtain characteristic fingerprints for *Candida* species on a variety of media, which could provide the clinical mycologist with a simple rapid tool for *Candida* species identification.


Introduction

Fungal infections both superficial and deep have been on the increase over the past decade. These nave been correlated with an increase in the number of immunocompromised patients as a result of the human immunodeficiency virus (HIV) pandemic and the increased use of immunosuppressive therapy for cancer treatment/organ transplantation patients¹.

The British Society for Medical Mycology (BSMM) currently recommends that yeast isolates should be identified to species level, as the correct antifungal treatment can usually be selected based upon the species identification. This also allows the mycologist to gain a better understanding of the epidemiology and possibly pin-point outbreak situations².

Current methods of identification rely heavily on sugar assimilation and fermentation tests, together with colony and microscopic morphology. There are several commercial kits available for yeast identification from pure culture. They can be time consuming and labour intensive, requiring between 24-72 hours for identification. CHROMagar is an alternative method based on colony colour. The plates are read at 48h & 72 hours and depend upon colour changes e.g. light green (C.albicans) and dark green (C.dubliniensis) colonies. This can lead to errors due to such subtle differences. More recently molecular methods (e.g. PCR, RAPD, AFLP) have been reported as useful when identifying Candida to species level and can reduce the time to identification to around 8 hours from pure culture. These techniques require a high level of skill, are expensive and not suitable to cope with a large sample through put.

It is becoming essential to rapidly identify *Candida* species to ensure appropriate antifungal therapy and hospital control measures can be put in place. In this paper we intend explore the possibility of using MALDI-TOF MS as a method to rapidly identify Candida species in minutes rather than hours.



in both incubation conditions.

Rapid Candida Species Identification; Is MALDI-TOF MS The Answer?

H. Sutton¹, D. Dare¹, S. Clements², C. Kibbler², E. Johnson³, M. Lunt⁴, H. Shah⁵; H.E.Sutton@mmu.ac.uk